• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Arctic Bioscience - Data on systemic inflammation published in Frontiers in Medicine

ABSRegulatory press release05.08.2026, 08.06
Read the release

Arctic Bioscience announces that new data on resolution of systemic inflammation in psoriasis and herring roe oil (HRO) has been published in the peer-reviewed journal Frontiers in Medicine. This was a post-hoc examination of blood-based markers of inflammation in patients who participated in the Haukeland psoriasis clinical trial (2019).

The analysis found that patients with mild-to-moderate psoriasis who received herring roe oil for 26 weeks showed significant reduction in several biomarkers of inflammation compared with placebo. These biomarkers can provide information about inflammation throughout the body. The findings also suggest that certain biomarkers may help identify which patients are most likely to benefit from treatment.

"Psoriasis is often thought of as a skin disease, but it can affect the whole body. These findings help us better understand what may be happening beneath the skin surface, and the research is part of our commitment to improving patients' health and quality of life", says Medical Director, Runhild Gammelsæter.

"Systemic inflammation can play an important role in psoriasis, even in patients with milder disease. The reductions observed in these inflammatory biomarkers suggest that herring roe oil may help support the body's natural processes for resolving inflammation. We look forward to publishing further data on these biomarkers from the larger HeROPA Phase 2b clinical trial on HRO350", concludes Gammelsæter.

HRO350 is an investigational medicinal product currently being developed as a potential new oral treatment for mild-to-moderate psoriasis, a large patient population that continues to need effective therapies with favorable safety and tolerability profiles. The data on systemic inflammation will be important in the ongoing planning of a potential Phase 3 clinical trial.

The research was carried out in collaboration with Dr. Kåre Steinar Tveit at Haukeland University Hospital in Norway.

Reference:
Ringheim-Bakka TA, Gammelsaeter R and Tveit KS (2026) Resolution of systemic inflammation in psoriasis following herring roe oil treatment: a post hoc analysis on inflammatory biomarkers in non-severe psoriatic patients. Front. Med. 13:1861341.

doi: 10.3389/fmed.2026.1861341.

Link to publication:

https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2026.1861341/full

The publication will be made available on the IR tab on the company's webpage.